Lawrence Otto  Klein net worth and biography

Lawrence Klein Biography and Net Worth

Dr. Klein has served as our Chief Operating Officer since January 2020 and remains responsible for business development activities; before that, Dr. Klein served as our Chief Business Officer from January 2019 to January 2020, our Senior Vice President, Business Development and Strategy from November 2017 through December 2018 and as our Vice President, Strategy from February 2016 to November 2017. Before joining our company, from October 2014 to February 2016, Dr. Klein was an Associate Partner at McKinsey & Company, where he was a leader in the biotech practice and served a number of biotechnology companies on a wide range of topics from strategy to operations. Dr. Klein received a Ph.D. from Stanford University, where he conducted research in the field of T cell immunology, and he holds a B.S. from the University of Wisconsin at Madison. Dr. Klein also has served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN), a biotechnology company, since September 2019 and Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company, since September 2021.

What is Lawrence Otto Klein's net worth?

The estimated net worth of Lawrence Otto Klein is at least $1.31 million as of January 15th, 2021. Dr. Klein owns 28,666 shares of CRISPR Therapeutics stock worth more than $1,313,189 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Klein may own. Additionally, Dr. Klein receives a salary of $675,000.00 as COO at CRISPR Therapeutics. Learn More about Lawrence Otto Klein's net worth.

How old is Lawrence Otto Klein?

Dr. Klein is currently 40 years old. There are 4 older executives and no younger executives at CRISPR Therapeutics. The oldest executive at CRISPR Therapeutics is Dr. Matthew Porteus M.D., Ph.D., Scientific Founder & Advisory Board Member, who is 56 years old. Learn More on Lawrence Otto Klein's age.

What is Lawrence Otto Klein's salary?

As the COO of CRISPR Therapeutics AG, Dr. Klein earns $675,000.00 per year. The highest earning executive at CRISPR Therapeutics is Dr. Samarth Kulkarni, CEO & Director, who commands a salary of $1,180,000.00 per year. Learn More on Lawrence Otto Klein's salary.

How do I contact Lawrence Otto Klein?

The corporate mailing address for Dr. Klein and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Lawrence Otto Klein's contact information.

Has Lawrence Otto Klein been buying or selling shares of CRISPR Therapeutics?

Lawrence Otto Klein has not been actively trading shares of CRISPR Therapeutics during the past quarter. Most recently, Lawrence Otto Klein sold 25,000 shares of the business's stock in a transaction on Friday, January 15th. The shares were sold at an average price of $215.20, for a transaction totalling $5,380,000.00. Following the completion of the sale, the chief operating officer now directly owns 28,666 shares of the company's stock, valued at $6,168,923.20. Learn More on Lawrence Otto Klein's trading history.

Who are CRISPR Therapeutics' active insiders?

CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Julianne Bruno (COO), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), Raju Prasad (CFO), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.

Are insiders buying or selling shares of CRISPR Therapeutics?

In the last year, insiders at the sold shares 14 times. They sold a total of 192,740 shares worth more than $12,514,312.47. The most recent insider tranaction occured on November, 11th when CEO Samarth Kulkarni sold 30,000 shares worth more than $1,668,600.00. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.

Information on this page was last updated on 11/11/2024.

Lawrence Otto Klein Insider Trading History at CRISPR Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/15/2021Sell25,000$215.20$5,380,000.0028,666View SEC Filing Icon  
6/24/2020Sell65,088$75.93$4,942,131.8458,666View SEC Filing Icon  
5/11/2020Sell25,000$60.40$1,510,000.0045,000View SEC Filing Icon  
7/11/2019Sell20,000$50.02$1,000,400.0031,579View SEC Filing Icon  
See Full Table

Lawrence Otto Klein Buying and Selling Activity at CRISPR Therapeutics

This chart shows Lawrence Otto Klein's buying and selling at CRISPR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CRISPR Therapeutics Company Overview

CRISPR Therapeutics logo
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Read More

Today's Range

Now: $45.81
Low: $45.61
High: $47.21

50 Day Range

MA: $47.96
Low: $44.90
High: $54.86

2 Week Range

Now: $45.81
Low: $43.42
High: $91.10

Volume

415,110 shs

Average Volume

1,480,623 shs

Market Capitalization

$3.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67